Skip to main content

Brachytherapy: Update and results

Current Urology Reports volume 4, pages 233–239 (2003)Cite this article

Abstract

Prostate cancer is the most common noncutaneous malignancy and the second most common cause of cancer mortality in American men. Treatment options for these patients include radical prostatectomy, external beam radiation therapy, hormonal therapy, and prostate brachytherapy. Patients with clinically and radiographically localized disease, especially young patients with few comorbid illnesses, are good candidates for prostate brachytherapy. Prostate brachytherapy has gained widespread acceptance throughout the past two decades and data from several large series of patients are now available. This article describes current techniques, treatment issues, and clinical results of permanent seed implants.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References and Recommended Reading

  1. American Cancer Society: Cancer Facts and Figures: 2002. Atlanta: American Cancer Society; 2002.

    Google Scholar 

  2. Barringer BS: Radium in the treatment of carcinoma of the bladder and prostate. JAMA 1917, 68:1227–1230.

    Google Scholar 

  3. Charyulu KKN: Transperineal interstitial implantation of prostate cancer: a new method. Int J Radiat Oncol Biol Phys 1980, 6:1261–1266.

    PubMed  CAS  Google Scholar 

  4. Kumar PP, Bartone FF: Transperineal percutaneous I-125 implant of the prostate. Urology 1981, 17:238–240.

    PubMed  Article  CAS  Google Scholar 

  5. Holm HH, Juul N, Pedersen JF, et al.: 125-Iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983 130:283–286.

    PubMed  CAS  Google Scholar 

  6. Nag S: Transperineal iodine-125 implantation of the prostate under transrectal ultrasound and fluoroscopic control. Endocurie Hyperthermi Oncol 1985, 1:207–211.

    Google Scholar 

  7. Ling CC: Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 1992, 23:81–87.

    PubMed  CAS  Google Scholar 

  8. Blasko JC, Grimm PD, Ragde H: Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol 1993, 3:240–249.

    Article  PubMed  Google Scholar 

  9. Wallner K, Merrick G, True L, et al.: I-125 versus Pd-103 for lowrisk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial. Cancer J 2002, 8:67–73.

    PubMed  Article  Google Scholar 

  10. Wallner KE, Roy J, Harrison L: Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1995, 32:465–471.

    PubMed  Article  CAS  Google Scholar 

  11. Wallner K, Blasko J, Dattoli M: Evaluation. In Prostate Brachytherapy Made Complicated. Edited by Wallner K, Blasko J, Dattoli M. Seattle: SmartMedicine Press; 1997:10.1–10.27.

    Google Scholar 

  12. Zelefsky MJ, Leibel SA, Gaudin PB, et al.: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998, 41:491–500.

    PubMed  Article  CAS  Google Scholar 

  13. DiBiase SJ, Hosseinzadeh K, Gullapalli RP, et al.: Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002 52:429–438.

    PubMed  Article  Google Scholar 

  14. Wright GL, Haley C, Beckett ML, et al.: Expression of prostatespecific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995, 1:18–28.

    Google Scholar 

  15. Silver DA, Pellicer I, Fair WR, et al.: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997, 3:81–85.

    PubMed  CAS  Google Scholar 

  16. Ellis RJ, Sodee DB, Spirnak JP, et al.: Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000, 48:483–487.

    Article  Google Scholar 

  17. Ellis RJ, Kim EY, Conant R, et al.: Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys 2001, 49:1281–1286.

    PubMed  Article  CAS  Google Scholar 

  18. Wallner K, Blasko J, Dattoli M: Implant alone vs. implant+EBRT. In Prostate Brachytherapy Made Complicated. Edited by Wallner K, Blasko J, Dattoli M. Seattle: Smart Medicine Press; 1997:12.1–12.29.

    Google Scholar 

  19. D’Amico AV, Coleman CN: Role of radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. J Clin Oncol 1996, 14:304–315.

    PubMed  CAS  Google Scholar 

  20. Nag S, Beyer D, Friedland J, et al.: American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999, 44:789–799.

    PubMed  Article  CAS  Google Scholar 

  21. Wallner K, Blasko J, Dattoli M: Who can’t have an implant? In Prostate Brachytherapy Made Complicated. Edited by Wallner K, Blasko J, Dattoli M. Seattle: Smart Medicine Press; 1997:13.1–13.11.

    Google Scholar 

  22. Wallner K, Lee H, Wasserman S, Dattoli M: Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 1997, 37:565–569.

    PubMed  Article  CAS  Google Scholar 

  23. Wallner K, Blasko J, Dattoli M: Implant alone vs. implant+EBRT. In Prostate Brachytherapy Made Complicated. Edited by Wallner K, Blasko J, Dattoli M. Seattle: Smart Medicine Press; 1997:12.1–12.29.

    Google Scholar 

  24. Wallner K, Blasko J, Dattoli M. Morbidity. In Prostate Brachytherapy Made Complicated. Edited by Wallner K, Blasko J, Dattoli M. Seattle: Smart Medicine Press; 1997:16.1–16.17.

    Google Scholar 

  25. Hu K, Wallner KE: Urinary incontinence in patients who have TURP/TUIP following prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998, 40:783–786.

    PubMed  Article  CAS  Google Scholar 

  26. Wallner K: Iodine 125 brachytherapy for early stage prostate cancer: new techniques may achieve better results. Oncology 1991, 5:115–126.

    PubMed  CAS  Google Scholar 

  27. Consensus statement: Guidelines for PSA following Radiation Therapy. Int J Radiat Oncol Biol Phys 1997, 37:1035–1041.

  28. Grado GL, Larson TR, Balch CS, et al.: Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys 1998, 42:289–298.

    PubMed  Article  CAS  Google Scholar 

  29. Zelefsky MJ, Hollister T, Raben A, et al.: Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000, 47:1261–1266. This paper describes the MSKCC experience with brachytherapy as monotherapy and details the method that many other centers use for stratifying implant patients by number of risk factors.

    PubMed  Article  CAS  Google Scholar 

  30. Ragde H, Elgamal A, Snow P, et al.: Ten-year disease free survival after transperineal sonography-guided Iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998, 83:989–1001.

    PubMed  Article  CAS  Google Scholar 

  31. Ragde H, Korb LJ, Elgamal AA, et al.: Modern prostate brachytherapy: prostate specific antigen results in 219 patients with up to 12 years of observed follow up. Cancer 2000, 89:135–141. This paper describes the Seattle experience with seed implants and provides some of the longest published follow-up data available.

    PubMed  Article  CAS  Google Scholar 

  32. Blasko JC: An update on LDR permanent brachytherapy for prostate cancer. Presented at the 21st Annual Meeting of the American Brachytherapy Society. San Diego: May 23–25,1999.

  33. Blasko JC, Grimm PD, Sylsvester JE, et al.: The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000, 57:273–278.

    PubMed  Article  CAS  Google Scholar 

  34. Ellis RJ: Four-year biochemical outcome following radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma. Presented at the RSNA 88th Scientific Assembly and Annual Meeting. Chicago: December 1–6, 2002.

  35. Merrick GS, Butler WM, Galbreath RW, et al.: Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys 2001, 51:41–48. This group in West Virginia plans implants with larger treatment volumes than many other centers, but also publishes data showing excellent long-term disease control.

    PubMed  Article  CAS  Google Scholar 

  36. Dattoli M, Wallner K, Sorace R, et al.: 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys 1996, 35:875–879.

    PubMed  Article  CAS  Google Scholar 

  37. Merrick GD, Butler WM, Lief JH, et al.: Biochemical outcome for hormone-naïve intermediate-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external beam radiation. Brachytherapy 2002, 1:95–101. This paper reports excellent 6-year results for patients treated with a combination of external beam radiation and seed implant.

    PubMed  Article  Google Scholar 

  38. Grimm PD, Blasko JC, Sylvester JE, et al.: 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy. Int J Radiat Oncol Biol Phys 2001, 51:31–40.

    PubMed  Article  CAS  Google Scholar 

  39. Kwok Y, Dibiase SJ, Amin PP, et al.: Risk group stratification in patients undergoing permanent 125I brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys 2002, 53:588–594.

    PubMed  Article  Google Scholar 

  40. Stock RG, Stone NN: The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Semin Surg Oncol 1997, 13:454–460.

    PubMed  Article  CAS  Google Scholar 

  41. Critz FA: A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol 2002, 167:1310–1313.

    PubMed  Article  Google Scholar 

  42. Ellis RJ: Combination conformal radiotherapy and radioimmunoguided transperineal Pd-103 implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma. Presented at the 11th Annual International Brachytherapy Conference. Santa Fe: June 5, 2002.

  43. Lederman GS, Cavanagh W, Albert PS, et al.: Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys 2001, 49:1297–1303.

    PubMed  Article  CAS  Google Scholar 

  44. Singh A, Zelefsky MJ, Raben A, et al.: Combined 3-dimensional conformal radiotherapy and transperineal Pd-103 permanent implantation for patients with intermediate and unfavorable risk prostate cancer. Int J Cancer (Radiat Oncol Invest) 2000, 90:275–280. This paper details the MSKCC experience with combination therapy for intermediate- and high-risk prostate cancer.

    Article  CAS  Google Scholar 

  45. Zeitlin SI, Sherman J, Raboy A, et al.: High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol 1998, 160:91–96.

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Radiation Oncology, Aultman Hospital, PO Box 80468, 44708, Canton, OH, USA

    Rodney J. Ellis MD & Edward Kim MD

Authors
  1. Rodney J. Ellis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ellis, R.J., Kim, E. Brachytherapy: Update and results. Curr Urol Rep 4, 233–239 (2003). https://doi.org/10.1007/s11934-003-0075-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-003-0075-2

Keywords

  • Prostate Cancer
  • Gleason Score
  • Radiat Oncol Biol Phys
  • Combination Therapy Group
  • Prostate Brachytherapy